These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?". Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL Clin Pharmacokinet; 2020 Feb; 59(2):277-279. PubMed ID: 31802398 [No Abstract] [Full Text] [Related]
16. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110 [TBL] [Abstract][Full Text] [Related]
17. Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?". Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL Clin Pharmacokinet; 2020 Feb; 59(2):269-271. PubMed ID: 31802401 [No Abstract] [Full Text] [Related]